Abdel-Aziz A.K.; Saadeldin M.K.; D'Amico P.; Orecchioni S.; Bertolini F.; Curigliano G.; Minucci S.
(Elsevier Ltd, 2019)
The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative ...